Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
PHAR Pharming Group
11.760
+0.010+0.09%
Post Mkt Price
11.7600.0000.00%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Assets
Current assets
Cash, cash equivalents and short term investments
2.94% 188.7M 0.84% 189.96M -8.04% 189.67M -6.60% 191.92M
-Cash and cash equivalents
2.94% 188.7M 0.84% 189.96M -8.04% 189.67M -6.60% 191.92M
Receivables
-12.13% 28.83M -12.48% 32.88M -4.37% 31.45M -13.60% 27.59M
-Accounts receivable
-12.13% 28.83M -12.48% 32.88M -4.37% 31.45M -23.25% 18.08M
-Taxes receivable
-- -- -- -- -- -- 17.73% 7.15M
-Other receivables
-- -- -- -- -- -- 2.36% 2.36M
Inventory
33.51% 33.51M 39.53% 33.93M 36.27% 29.61M 28.88% 27.31M
Prepaid assets
-- -- -- -- -- -- -40.54% 2.39M
Restricted cash
3.03% 1.01M -78.84% 209K -76.91% 222K -77.21% 227K
Total current assets
4.07% 252.05M 2.28% 256.98M -4.15% 250.95M -5.38% 249.44M
Non current assets
Net PPE
-26.68% 27.78M -20.42% 29.96M 45.78% 31.9M 52.93% 33.17M
-Gross PPE
-26.68% 27.78M -20.42% 29.96M 45.78% 31.9M 36.53% 55.94M
-Accumulated depreciation
-- -- -- -- -- -- -18.08% -22.77M
Goodwill and other intangible assets
-21.21% 70.12M -17.13% 75.77M -9.42% 81.32M -11.04% 83.83M
-Other intangible assets
-- -- -- -- -- -- -11.04% 83.83M
Investments and advances
7.65% 10.78M 60.12% 11.63M 10.36% 7.4M 21.34% 8.65M
Non current deferred assets
-1.32% 21.19M -22.31% 18.59M -26.59% 20.19M -33.55% 21.22M
Non current prepaid assets
5.88% 210K -- 223K -- 238K -- 194K
Other non current assets
40.36% 197K 51.06% 746K -7.50% 797K 59.08% 812K
Total non current assets
-17.92% 130.28M -14.83% 136.92M -3.33% 141.85M -4.90% 147.87M
Total assets
-4.64% 382.32M -4.40% 393.9M -3.86% 392.8M -5.20% 397.32M
Liabilities
Current liabilities
Payables
1.42% 42.74M 4.48% 45.07M -6.37% 40.83M -36.03% 9.14M
-accounts payable
1.42% 42.74M 4.48% 45.07M -6.37% 40.83M -43.67% 7.6M
-Total tax payable
-- -- -- -- -- -- 143.75% 1.51M
-Other payable
-- -- -- -- -- -- -80.67% 34K
Current accrued expenses
-- -- -- -- -- -- -0.37% 33.34M
Current debt and capital lease obligation
-12.55% 3.95M -10.91% 4.12M -12.82% 4.32M 7.22% 4.3M
-Current debt
-15.35% 1.63M -12.37% 1.73M -39.66% 1.84M -8.03% 1.88M
-Current capital lease obligation
-10.47% 2.32M -9.82% 2.39M 30.27% 2.48M 23.08% 2.42M
Current liabilities
-0.05% 46.69M 2.84% 49.19M -38.74% 45.15M -39.23% 46.77M
Non current liabilities
Long term debt and capital lease obligation
-15.62% 135.23M -12.64% 144.88M 3.24% 153.46M -0.47% 157.46M
-Long term debt
-14.86% 120.01M -11.87% 128.24M -3.80% 135.56M -7.31% 139.01M
-Long term capital lease obligation
-21.19% 15.23M -18.15% 16.65M 131.56% 17.9M 123.90% 18.46M
Other non current liabilities
-62.98% 143K -19.67% 152K -14.17% 162K -22.46% 165K
Total non current liabilities
-15.74% 135.38M -12.64% 145.03M 3.22% 153.63M -0.50% 157.63M
Total liabilities
-12.20% 182.07M -9.18% 194.23M -10.68% 198.78M -13.17% 204.4M
Shareholders'equity
Share capital
3.08% 7.48M 2.96% 7.47M 3.97% 7.47M -5.45% 7.43M
-common stock
3.08% 7.48M 2.96% 7.47M 3.97% 7.47M -5.45% 7.43M
Retained earnings
12.45% -242.53M 8.46% -253.55M 3.68% -270.5M 13.97% -273.17M
Paid-in capital
1.33% 459.45M 1.13% 458.36M 2.15% 457.96M -6.72% 455.25M
Gains losses not affecting retained earnings
-344.78% -24.15M -185.93% -12.61M -108.03% -910K -36.32% 3.4M
Total stockholders'equity
3.47% 200.25M 0.76% 199.67M 4.30% 194.02M 5.00% 192.92M
Total equity
3.47% 200.25M 0.76% 199.67M 4.30% 194.02M 5.00% 192.92M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion with Explanation

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World. The company was founded on November 11, 1988 and is headquartered in Leiden, the Netherlands.
CEO: Dr. Sijmen (Simon) de Vries, M.D.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist